Amylyx competitors

Chaim Lebovits has been at the forefront of mining and natural resource management in African regions for over a decade. He has spent years leading the exploration and development of resources in the Democratic Republic of Congo on behalf of world-leading firms. In this capacity, he has negotiated numerous, highly-successful deals on behalf of both African governments and global mining concerns. As an internationally known and respected business mogul and corporate manager, Lebovits has developed excellent personal relations with numerous African leaders, and has promoted the interests of their countries in the economic and political capitals of the world, both in official and unofficial capacities. Lebovits leads ACC HOLDINGS INTERNATIONAL and its many subsidiaries with his extensive experience and passion for the mining, oil, and energy industry, with intentions of taking ACC to a level of excellence and leadership in the resource mining sector. His commitment to the people that work with him, and to health, environmental and social issues, is evident in his projects in Africa. Lebovits into BrainStorm through ACCBT (ACC BioTech). ACCBT is one of ACC's subsidiaries that is totally focused on biotechnology. Originally from New York, Lebovits moved to Israel and now resides in Jerusalem. Lebovits has worked in senior positions for the worldwide Chabad Lubavitch organization and in the mining business, and launched his own private companies in 2005. Lebovits now splits his time between North America, Europe, Africa, and the Middle East.

As a senior executive with 20+ years of sell- and buy- side business and corporate development experience, my career encompasses roles in therapeutics, biotech, genomics, medical devices, and pharmacy benefits. During my tenure at Pfizer, I completed more than 2 dozen acquisition, co-development, and licensing deals ranging from $300M to $7B. Later at Foundation Medicine, I led the $1B sale of their genomics testing to Roche, and earlier played a leadership role in Medco’s $29B sale to Express Scripts. I have worked extensively within R&D environments and launched 3 $1B+ therapeutic products in the hypertension and antibiotics categories. Additionally, I have been the CEO of early stage start-ups, building the funding, commercialization, and exit strategy for therapeutics companies in the CNS and autoimmune disease space.Currently, as CEO of Cognition Therapeutics, I am driving Series C fundraising effort. With multiple phase 2 clinical trials well under way for the Alzheimer’s research and more than a hundred million dollars in dedicated funding, I am repositioning the company to broaden the focus on our science and other CNS clinical conditions. I am pleased to lead a company dedicated to halting neurological disease processes and restoring and preserving the building blocks of brain health and function and look forward to sharing our progress here.

Paul Brennan is a Senior VP:Business Devpt at Aspreva Pharmaceuticals, Board Member at Nervgen Pharma Corp, and President/CEO at Nervgen Pharma Corp and is based in Vancouver Canada Area. He has worked as Board Member at MIGENIX Inc, Board Member at Biowest Therapeutics Inc, and Chief Executive Officer at Biowest Therapeutics Inc. Paul attended Queen's University between 1987 and 1989.